China’s INFevo has completed a Pre-A round exceeding RMB 100 million, according to a November 16 announcement by investor Xinglian Capital.

The company develops virtual-cell models that link computational predictions with automated laboratory experiments. Funding will support that infrastructure and research partnerships.

For biological AI, reproducible experimental validation is a crucial step beyond a computational prediction. The financing announcement does not establish clinical efficacy for any future drug.